[Thrombolytic agents].

Abstract

The clinical efficacy of thrombolytic agents, urokinase, lysyl-plasminogen and batroxobin, was evaluated on the patients with deep venous thrombosis. In the group treated with combination of batroxobin, lysyl-plasminogen and urokinase, significantly better efficacy was obtained over the urokinase group in terms of judgement on venography and clinical improvement. Plasma fibrinogen, plasminogen and alpha 2-plasmin inhibitor were markedly reduced by batroxobin infusion. Fibrinolytic activity measured by plasminogen-free fibrin plate method was detected in 89% of blood samples taken after 120,000 I.U. urokinase infusion following lysylplasminogen administration. These results suggested that even moderate dosage of urokinase could induce fibrinolytic activity under conditions of low alpha 2-plasmin inhibitor and fibrinogen levels caused by batroxobin and additional lysylplasminogen.

• Authors: K Furukawa
• Journal: Nihon Geka Gakkai zasshi (Nihon Geka Gakkai Zasshi) Vol. 85 Issue 9 Pg. 1166-9 (Sep 1984) ISSN: 0301-4894 [Print] Japan
• PMID: 6503980 (Publication Type: English Abstract, Journal Article)

Chemical References

• Fibrinolytic Agents
• Peptide Fragments
• lysyl-plasminogen
• Plasminogen
• Batroxobin
• Urokinase-Type Plasminogen Activator

Topics

• Batroxobin (therapeutic use)
• Drug Evaluation
• Fibrinolytic Agents (therapeutic use)
• Humans
• Peptide Fragments (therapeutic use)
• Plasminogen (therapeutic use)
• Thrombophlebitis (drug therapy)
• Urokinase-Type Plasminogen Activator (therapeutic use)